Results 71 to 80 of about 962,920 (362)

Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. [PDF]

, 2018
BackgroundThe value of induction chemotherapy (ICT) remains under investigation despite decades of research. New advancements in the field, specifically regarding the induction regimen of choice, have reignited interest in this approach for patients with
Cohen, EEW, Haddad, RI, Hitt, R, Lefebvre, J-L, Posner, M, Schulten, J, Vermorken, JB   +6 more
core   +1 more source

A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini, Ezgi Oner, Mark P. Ward, Sinead Hurley, Brian David Henderson, Faye Lewis, Stephen P. Finn, Gerard J. Fitzmaurice, John J. O'Leary, Sharon O'Toole, Lorraine O'Driscoll, Kathy Gately   +11 more
wiley   +1 more source

Hypofractionated stereotactic radiotherapy for brain metastases in lung cancer patients: dose‒response effect and toxicity

Discover Oncology
Background Lung cancer is a common cause of brain metastases, approximately 40% of patients with lung cancer will develop brain metastases at some point during their disease.
Kaicheng Pan, Bing Wang, Xiao Xu, Jiafeng Liang, Yi Tang, Shenglin Ma, Bing Xia, Lucheng Zhu   +7 more
doaj   +1 more source

Inhibition of IKK-NFκB pathway sensitizes lung cancer cell lines to radiation

Cancer Biology & Medicine, 2017
Objective : Cancer cell radioresistance is a stumbling block in radiation therapy. The activity in the nuclear factor kappa B (NFκB) pathway correlates with anti-apoptotic mechanisms and increased radioresistance.
Avgi Tsolou, Maria Liousia, Dimitra Kalamida, Stamatia Pouliliou, Alexandra Giatromanolaki, Michael Koukourakis   +5 more
doaj   +1 more source

Management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery?

Radiation Oncology, 2022
Introduction The first line of treatment for nonfunctioning pituitary adenoma (NFPA) is surgery. Adjuvant radiotherapy or surveillance and new treatment (second surgical operation or salvage radiotherapy) in case of recurrence are options discussed at ...
Thomas Charleux, Véronique Vendrely, Aymeri Huchet, Renaud Trouette, Amandine Ferrière, Antoine Tabarin, Vincent Jecko, Hugues Loiseau, Charles Dupin   +8 more
doaj   +1 more source

Antiangiogenics and radiotherapy

Journal of Pharmacy and Pharmacology, 2008
Abstract Antiangiogenic therapies are one of the fore-runners of the new generation of anticancer drugs aimed at tumour-specific molecular targets. Up until the beginning of this century, the general opinion was that targeted agents should show antitumour activity when used as single agents.
Shannon, Aoife M., Williams, Kaye J.
openaire   +4 more sources

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

Molecular Oncology, EarlyView.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi, Janelle‐Cheri Millen, Romela Irene Ramos, Jennifer A. Linehan, Timothy G. Wilson, Dave S. B. Hoon, Matias A. Bustos   +6 more
wiley   +1 more source

Radiosurgery of limited brain metastases from primary solid tumor: results of the randomized phase III trial (NCT02355613) comparing treatments executed with a specialized or a C-arm linac-based platform

Radiation Oncology, 2023
Background Comparative prospective data regarding different radiosurgery (SRS) modalities for treating brain metastases (BMs) from solid tumors are not available. To investigate with a single institute phase III randomized trial whether SRS executed with
Marta Scorsetti, Pierina Navarria, Luca Cozzi, Elena Clerici, Luisa Bellu, Davide Franceschini, Antonio Marco Marzo, Ciro Franzese, Valter Torri, Giacomo Reggiori, Francesca Lobefalo, Luca Raspagliesi, Luca Attuati, Federico Pessina, Andrea Franzini, Piero Picozzi, Stefano Tomatis   +16 more
doaj   +1 more source

KRAS and GNAS mutations in cell‐free DNA and in circulating epithelial cells in patients with intraductal papillary mucinous neoplasms—an observational pilot study

Molecular Oncology, EarlyView.
This study demonstrates that KRAS and GNAS mutations are more prevalent in patients with resected intraductal papillary mucinous neoplasms (IPMN) compared to those under clinical surveillance. GNAS mutations significantly differ between the two patient cohorts, indicating that their absence may serve as a potential biomarker to support conservative ...
Christine Nitschke, Marie Tölle, Philipp Walter, Kira Meißner, Mara Goetz, Jolanthe Kropidlowski, Andreas W. Berger, Jakob R. Izbicki, Felix Nickel, Thilo Hackert, Klaus Pantel, Harriet Wikman, Faik G. Uzunoglu   +12 more
wiley   +1 more source

Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer : a phase II trial [PDF]

, 2017
Background: Neo-adjuvant chemotherapy followed by radical cystectomy with extended pelvic lymph node dissection is considered to be the treatment of choice for patients with muscle invasive bladder cancer (MIBC).
De Meerleer, Gert, Decaestecker, Karel, Dirix, Piet, Fonteyne, Valerie, Junius, Sara, Ost, Piet, Rammant, Elke, Swimberghe, Martijn   +7 more
core   +1 more source